AbbVie Inc. (ABBV)
| Market Cap | 385.20B |
| Revenue (ttm) | 56.33B |
| Net Income (ttm) | 4.24B |
| Shares Out | 1.77B |
| EPS (ttm) | 2.39 |
| PE Ratio | 91.36 |
| Forward PE | 17.80 |
| Dividend | $6.56 (3.00%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 3,832,291 |
| Open | 209.99 |
| Previous Close | 214.29 |
| Day's Range | 209.20 - 218.66 |
| 52-Week Range | 153.58 - 218.66 |
| Beta | 0.60 |
| Analysts | Strong Buy |
| Price Target | 212.70 (-2.52%) |
| Earnings Date | Apr 25, 2025 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for ABBV stock is "Strong Buy." The 12-month stock price forecast is $212.7, which is a decrease of -2.52% from the latest price.
News
Darst's Stock Picks: GOLD, EL, ABBV
"We currently advise gradually shifting exposure away from high-growth areas toward more value and defensive sectors," notes David Darst. He discusses finding opportunities in an uncertain market.
AbbVie Inc. (ABBV) TD Cowen 45th Annual Health Care Conference (Transcript)
AbbVie Inc. (NYSE:ABBV) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET Company Participants Scott T. Reents - Executive Vice President and Chief Financial Officer Jeffrey R.
5 Big Biopharmaceutical Stocks That Are Finding Favor
AbbVie, Gilead Sciences, Amgen, and Johnson & Johnson have held steady amid a fluctuating market.
The Dividend Aristocrats Ranked By Quality Scores: March 2025
S&P Dow Jones Indices added three new members to the S&P 500 Dividend Aristocrats Index, expanding it to 69 companies. I rank Dividend Aristocrats by quality scores, presenting undervalued and overval...
Healthy Returns: AbbVie is the newest potential weight loss drug market player
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra's obesity drug. AI takes center stage at HIMSS conference gets underway in Vegas.
AbbVie to Present at the Leerink Partners Global Healthcare Conference
NORTH CHICAGO, Ill. , March 4, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025.
AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race
On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
AbbVie (ABBV) has agreed to license a weight-loss drug currently in development from Danish biotech firm Gubra for up to about $2.2 billion, signaling its entry in the obesity treatment market.
Final Trades: Taiwan Semi, Abbvie, Tradeweb Markets and the IYH
The Investment Committee give you their top stocks to watch for the second half.
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
HØRSHOLM, DK / ACCESS Newswire / March 03, 2025 / Gubra (CPH:GUBRA) Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide d...
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1 The primary endpoin...
AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
NORTH CHICAGO, Ill. , Feb. 26, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025.
Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here
Despite significant market events, industrial and tech stocks have had similar returns since 2020, indicating a potential long-term rotation favoring value stocks. Higher inflation and interest rates ...
Why AbbVie Remains A Strong Buy For Long-Term Investors
Why AbbVie Remains A Strong Buy For Long-Term Investors
How Dividend Investing Helps Parents Fund College Education Fees
More than half of parents in the United States emphasize paying for their child's college fees as a main concern. Start a UGMA custodial account early, and use the Dividend Growth Investing strategy t...
AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
Since my last analyses on JNJ and ABBV, both have released Q4 earnings. Overall, JNJ showed more pronounced unevenness in its Q4 results, while ABBV's growth story is pretty clear-cut. The goal of thi...
My Dividend Stock Portfolio: New January Dividend Record - 100 Holdings With 14 Buys
January saw solid investment activity with $1,500 in net capital added, primarily into Business Development Companies like Owl Rock Capital, Goldman Sachs BDC, and Blackstone Secured Lending Fund. Div...
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Announces Completion of Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials.
AbbVie Appears Ready To Move Higher
AbbVie shares recently rebounded, supported by strong earnings, positive guidance, and a late 2024 dividend increase, indicating the potential for further gains. Despite a $3.5 billion impairment char...
The Big 3: ABBV, EA, CEG
Today's Big 3 focuses on companies that couldn't be more different, but @ProsperTradingAcademy's Mike Shorr points to one thing they have in common: choppy price action. He talks about the trends he's...
AbbVie: An Undervalued Dividend Aristocrat
AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets like...
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025 NORTH CHICAGO, Ill. , Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its board of directors has...
All-In: The 23-Stock Six-Figure Dividend Portfolio I'm Betting My Future On
Thank you to the Seeking Alpha community for your support! Reaching 40,000 followers is a dream come true. Your feedback fuels my work. I've invested 91% of my net worth in 23 high-conviction dividend...
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill. , Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share.
Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
Allergan Medical Institute (AMI) Training Centers to offer most comprehensive, training programs accelerating providers' consultative and clinical skills Innovative curriculum will empower providers t...